glp-1 lafayette and Microbiome Repair for Long-Term Metabolism Lafayette Heath Care News |

Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 176,64 per year only 14,72 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

Intravenous administration of these formulations, particularly the combination of 131 I-ELP-POP and exendin-4-ELP-POP, resulted in marked tumor regression in insulinoma xenograft models

Small blood vessel disease of diabetes includes eye, kidney, and nerves of the feet

In regard to thermoregulation, which refers to the bodys ability to control its temperature, by losing body fat, youre losing insulation, so thereby it follows that youre less tolerant to the cold, says Dr